did not modify plasma aldosterone levels in 1. Angiotensin I1 was infused at stepwise increasing dose rates (2, 4 and 10 pmol min-' kg-I) in 12 normal subjects. Infusions were performed in the presence of normocalcaemia, mild hypercalcemia induced by concomitant calcium gluconate infusion, and after 2 weeks of treatment with nifedipine.
1. Angiotensin I1 was infused at stepwise increasing dose rates (2, 4 and 10 pmol min-' kg-I) in 12 normal subjects. Infusions were performed in the presence of normocalcaemia, mild hypercalcemia induced by concomitant calcium gluconate infusion, and after 2 weeks of treatment with nifedipine.
2. Pre-infusion plasma levels of angiotensin 11, renin or aldosterone were not altered by acute mild hypercalcaemia or administration of nifedipine. The angiotensin 11-induced increases in plasma aldosterone were also similar under the three study conditions.
3. Variations in calcium metabolism occurring under clinical conditions appear to play a minor subjects with mildiy impaired renal function 131 but caused aldosterone stimulation in patients with terminal renal failure 141. On the other hand, in six normal subjects the responsiveness of aldosterone to ANG I1 was reported to be blunted acutely after administration of a single dose of the calcium inhibitor nifedipine 151.
Whether and to what extent such an effect may persist in the stable phase of pharmacological intervention with calcium antagonists is unknown. Therefore, the present study was undertaken to assess the influence of a mild elevation in plasma calcium or of nifedipine given for 2 weeks on aldosterone responsiveness to ANG I1 in normal subjects. role in modulating the angiotensin 11-dependent pathway of aldosterone regulation in normal
Introduction
Experiments in vitro indicated that calcium may modify the responsiveness of aldosterone production to corticotropin, angiotensin I1 (ANG 11) or potassium [ l , 21. However, the relevance of this cation in the regulation of aldosterone metabolism in man has not been clarified. Acute hypercalcaemia induced by intravenous infusion instructed to ingest a normal diet, avoiding very high or low sodium intakes 161. Under these dietary conditions, urinary sodium and potassium averaged 188 f SEM 29 and 78 f 8 mmo1/24 h respectively on the first day and 168 f 21 or 72 k 8 mmo1/24 h on the last day of the study. infusion pump) in the supine position, ANG I1 (Hypertensin) was infused at stepwise increasing dose rates of 2 , 4 and 10 pmol min-' kg-' during 20 min each. At the end of the equilibration period, basal blood pressure and heart rate were obtained and blood was collected from the arm contralateral to the infusion for determination of plasma sodium, potassium, calcium, renin activity, ANG I1 and aldosterone levels. Plasma ANG 11, aldosterone and, at the highest dose rate, calcium levels were measured at the end of each ANG I1 infusion step.
(B) After the equilibration period described above (procedure A), calcium gluconate was infused at constant rate (8-3 pmol of calcium min-' kg-') during 120 min. Blood pressure, heart rate, plasma renin, aldosterone and calcium levels were determined at the end of the equilibration and of the calcium infusion periods.
(C) After a 60-120 min equilibration period with intravenous infusion of calcium gluconate at constant rate (8.3 pmol of calcium min-' kg-') in the supine position, ANG I1 was infused in addition to calcium gluconate at increasing dose rates of 2, 4 and 10 pmol min-I kg-' during 20 min each. Blood was collected at the end of the equilibration period and of each ANG I1 infusion step for determination of plasma calcium, ANG I1 and aldosterone levels.
(D) After completion of these procedures, the subjects were started on oral nifedipine, 10-20 mg thrice daily (mean dose 48 k 3 mg/day). The lower dose had to be used in five subjects, who developed headache at the higher doses. After 2 weeks of nifedipine treatment, an ANG I1 infusion study was performed according to procedure (A) protocol. All subjects took the usual morning dose of nifedipine before the test.
Blood pressure and heart rate were monitored at 1-2 min intervals during procedures (A)-(D). Plasma sodium and potassium were determined by flame photometer, calcium by Autoanalyzer, ANG 11, aldosterone and renin activity by radioimmunoassay [7-91. Data were analysed by analysis of variance and modified t-test; regressions were compared by analysis of covariance.
Results
Under basal conditions (procedure A), mean pre-ANG I1 infusion blood pressure and heart rate were 109/65 f 3/2 mmHg and 65 f 3 beats/min; plasma sodium, potassium, calcium and renin activity averaged 139 & 1 mmol/l, 4.0 0.1 mmol/l, 2.27 f 0.02 mmol/l and 1.4 i-0.4 nmol h-I ml-1 respectively. These values ). Blood pressure, heart rate, plasma calcium and renin measured before calcium infusion (procedure B), and blood pressure, heart rate and plasma renin activity measured before the combined calcium ANG I1 infusion (procedure C), were comparable with the corresponding values obtained before procedures (A) and (D). However, during the calcium infusion preceding the combined calcium-ANG I1 infusion, plasma calcium increased from 2.25 k 0.02 to 2.64 Pre-infusion plasma levels of ANG I1 and aldosterone were similar when measured before ANG I1 infusion (procedure A), the combined calcium-ANG I1 infusion (procedure C) or the ANG I1 infusion under nifedipine (procedure D) (Fig. 1) . The increase in plasma ANG I1 during ANG I1 infusion was comparable in the three procedures (Fig. 1) ; the increase in plasma ANG I1 was accompanied by a parallel increase in plasma aldosterone, which was highly significant (P < 0.01) already at the lowest ANG I1 infusion rate. The ANG 11-induced increments in plasma aldosterone were similar in the three study procedures (Fig. 1) . ANG 11-induced increases in diastolic blood pressure at the dose rates of 2, 4 and 10 nmol min-' kg-I were similar under basal conditions (+7 i-1, +13 & 2 and +20 k 2 mmHg), in the presence of mild hypercalcaemia 0.04 mmol/l (P < 0.01).
(+4 f 1, +15 rf: 2 and +22 f 2 mmHg) or after nifedipine (+6 f 1, +12 f 2 and +22 f 2 mmHg). Heart rate did not change significantly during ANG I1 infusion in the three study conditions.
Calcium gluconate infused at constant rate during 120 min (procedure B) increased plasma calcium from 2.25 f 0.02 to 2.5 f 0.02 mmol/l ( P < O-Ol), but did not modify blood pressure (from 112/66 f 12/9 to 114/67 f 12/9 mmHg), heart rate (from 64 i-3 to 65 f 3 beatdmin), plasma renin activity (from 1.0 i-0.2 to 0.7 k 0.1 pmol h-I ml-') or aldosterone (from 310 f 50 to 29 1 rf: 30 pmol/l) levels.
Discussion
In the present study, neither the basal values of renin or aldosterone nor the responsiveness of plasma aldosterone to ANG I1 were modified during an acute mild increase in plasma calcium or by short-term administration of the calcium antagonist nifedipine. With the calcium infusion rate used, plasma calcium was increased from 2.25 i-0.02 to 2.64 f 0.04 mmolll. In a previous study from this laboratory 131, acute hypercalcaemia of a more marked degree also failed to alter plasma renin or aldosterone levels.
These observations do not militate against a role for calcium in the regulation of renin or aldosterone production. Calcium plays an important role in stimulation-secretion coupling of several endocrine systems [lo] and may be required for the biosynthesis of renin and aldosterone [ l l , 121. Moreover, it has been suggested that the stimulatory action of ANG I1 or potassium on aldosterone production may depend upon cellular uptake of calcium [131. However, such studies in vitro do not imply that in vivo a mild to moderate increase in plasma calcium or the degree of inhibition of transmembrane calcium influx achieved by pharmacological agents should necessarily result in shifts in intracellular calcium concentration or distribution capable of modifying hormone biosynthesis or release. Pharmacological rather than physiological extracellular calcium concentrations have been used in vitro to stimulate aldosterone production [ 121. Evidence for aldosterone inhibition by calcium antagonists has been obtained in vitro with lanthanum or verapamil but not nifedipine [131. In other studies with nifedipine, plasma renin levels were increased acutely after a single dose of the drug in normal or hypertensive subjects [ 141, but were unaltered after 6 weeks of treatment [15]. The possibility cannot be excluded that acute renin stimulation was mediated by a concomitant decrease in blood pressure or other haemodynamic effects of nifedipine rather than by a calcium-specific mechanism. Such an acute activation of the renin-ANG system may also have contributed to a blunting of ANG 11-induced increases in plasma aldosterone during the first 2 h after a single dose of nifedipine [51. The lack of effect of acute elevation in plasma calcium or short-term calcium inhibition with nifedipine suggest that variations in calcium metabolism occurring under clinical conditions play at most a minor role in modulating renin release and the ANG 11-dependent pathway of aldosterone production. Whether calcium may assume a more important role in corticotropin or potassiummediated aldosterone regulation in man remains to be evaluated. 
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